PDCD1 and hepatocellular carcinoma: Wong et al. reported a retrospective cohort study involving 25 HCC patients who had progressed on anti-PD-(L)1 therapy and were subsequently treated with a combination of ipilimumab and anti-PD-1 (nivolumab or pembrolizumab), demonstrating an ORR of 16%.